Top

Published in:

11-07-2023 | NSCLC

COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study

Authors: Hikmat Abdel-Razeq, Baha’ Sharaf, Mohammed J. Al-Jaghbeer, Hala Abu-Fares, Rayan Bater, Moataz Abu Shaer, Hala Abu-Jaish, Dima Abu Laban, Osama Salamah, Faris Tamimi, Khalid Ashouri, Tareq Salameh, Raed Zughul, Yazan Alhalaseh

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2023

Abstract

Cancer patients are at higher risk for venous thromboembolism (VTE). Several risk assessment models (RAM), including the Khorana and COMPASS-CAT, were developed to help predict the occurrence of VTE in cancer patients on active anti-cancer therapy. We aim to study the prevalence and predictors of VTE among patients with non-small cell lung cancer (NSCLC) and compare both RAMs in predicting VTE in patients with NSCLC were retrospectively reviewed. Variables known to increase the risk of VTE were collected and risk of VTE was assessed using both Khorana and COMPASS-CAT RAM. A total of 508 patients (mean age ± SD, 58.4 ± 12.2 years) were enrolled. Most (n = 357, 70.3%) patients had adenocarcinoma, and 333 (65.6%) patients had metastatic disease. VTE were confirmed in 76 (15.0%) patients. Rates were higher among patients with metastatic disease (19.8%, p < 0.001), adenocarcinoma (17.4%, p = 0.01) and those treated with immunotherapy (23.5%, p = 0.014). VTE rates were 21.2%, 14.1% and 13.9% among those with high (n = 66), intermediate (n = 341) and low (n = 101) Khorana risk scores, respectively (p = 0.126). On the other hand, 190 (37.4%) were classified as high risk by the COMPASS-CAT RAM; 52 (27.4%) of them had VTE compared to 24 (7.5%) of the remaining 318 (62.6%) classified as Low/Intermediate risk level, p < 0.001. In conclusion, patients with NSCLC are at high risk for VTE, especially those with adenocarcinoma, metastatic disease and when treated with immunotherapy. Compared to Khorana RAM, COMPASS-CAT RAM was better in identifying more patients in high-risk group, with higher VTE rate.

Available only for authorised users

Prandoni P, Falanga A, Piccioli A (2005) Cancer and venous thromboembolism. Lancet Oncol 6:401–410. https://doi.org/10.1016/S1470-2045(05)70207-2CrossRefPubMed

Horsted F, West J, Grainge MJ (2012) Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med 9. https://doi.org/10.1371/journal.pmed.1001275

Ay C, Pabinger I, Cohen AT (2017) Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 117:219–230. https://doi.org/10.1160/TH16-08-0615CrossRefPubMed

Khorana AA, Mackman N, Falanga A (2022) Cancer-associated venous thromboembolism. Nat Rev Dis Primers 8:11. https://doi.org/10.1038/s41572-022-00336-yCrossRefPubMed

Gade IL, Braekkan SK, Naess IA (2017) The impact of initial cancer stage on the incidence of venous thromboembolism: the scandinavian thrombosis and Cancer (STAC) cohort. J Thromb Haemost 15:1567–1575. https://doi.org/10.1111/jth.13752CrossRefPubMed

Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104:2822–2829. https://doi.org/10.1002/cncr.21496CrossRefPubMed

Abdel-Razeq H, Mansour A, Abdulelah H (2018) Thromboembolic events in cancer patients on active treatment with cisplatin-based chemotherapy: another look! Thromb J. https://doi.org/10.1186/s12959-018-0161-9. 16, 2:CrossRefPubMedPubMedCentral

Falanga A, Brenner B, Khorana AA, Francis CW (2022) Thrombotic complications in patients with cancer: advances in pathogenesis, prevention, and treatment-A report from ICTHIC 2021. https://doi.org/10.1002/rth2.12744. Res Pract Thromb Haemost 6:

Moik F, Chan WE, Wiedemann S (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137:1669–1678. https://doi.org/10.1182/blood.2020007878CrossRefPubMedPubMedCentral

10.

Sussman TA, Li H, Hobbs B et al (2021) Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival. J Immunother Cancer 9. https://doi.org/10.1136/jitc-2020-001719

11.

Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7–33. https://doi.org/10.3322/caac.21708CrossRefPubMed

12.

Lung Cancer Fact Sheet (2023) American lung association. Available at: https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet. Accessed 29

13.

Numico G, Garrone O, Dongiovanni V (2005) Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 103:994–999. https://doi.org/10.1002/cncr.20893CrossRefPubMed

14.

Song C, Shargall Y, Li H (2019) Prevalence of venous thromboembolism after lung surgery in China: a single-centre, prospective cohort study involving patients undergoing lung resections without perioperative venous thromboembolism prophylaxis†. Eur J Cardiothorac Surg 55:455–460. https://doi.org/10.1093/ejcts/ezy323CrossRefPubMed

15.

Dong H, Liang X, Gao Y (2022) Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: a single-center, prospective cohort study. Thorac Cancer 13:1258–1266. https://doi.org/10.1111/1759-7714.14373CrossRefPubMedPubMedCentral

16.

Hicks LK, Cheung MC, Ding K (2009) Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada clinical trials Group trials. Cancer 115:5516–5525. https://doi.org/10.1002/cncr.24596CrossRefPubMed

17.

Abdel-Razeq H, Mansour A, Saadeh SS (2018) The application of current proposed venous thromboembolism risk assessment model for ambulatory patients with cancer. Clin Appl Thromb Hemost 24:429–433. https://doi.org/10.1177/1076029617692880CrossRefPubMed

18.

Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119:648–655. https://doi.org/10.1002/cncr.27772CrossRefPubMed

19.

Falanga A, Gal GL, Carrier M (2021) Management of Cancer-Associated thrombosis: unmet needs and future perspectives. TH Open 5. https://doi.org/10.1055/s-0041-1736037

20.

Rutjes AW, Porreca E, Candeloro M et al (2020) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 12:008500. https://doi.org/10.1002/14651858CrossRef

21.

Gerotziafas GT, Mahé I, Lefkou E (2020) Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer. Thromb Res 191 Suppl 150–57. https://doi.org/10.1016/S0049-3848(20)30397-2

22.

Abdel-Razeq H, Ma’koseh M, Abdel-Razeq R et al (2021) The application of the lymphoma international prognostic index to predict venous thromboembolic events in diffuse large B-cell lymphoma patients. Front Oncol 11:677776CrossRefPubMedPubMedCentral

23.

Khorana AA, Kuderer NM, Culakova E et al (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907. https://doi.org/10.1182/blood-2007-10-116327CrossRefPubMedPubMedCentral

24.

Mulder FI, Candeloro M, Kamphuisen PW (2019) The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica 104:1277–1287. https://doi.org/10.3324/haematol.2018.209114CrossRefPubMedPubMedCentral

25.

Gerotziafas GT, Taher A, Abdel-Razeq H (2017) A predictive score for thrombosis Associated with breast, colorectal, lung, or ovarian Cancer: the prospective COMPASS-Cancer-Associated thrombosis study. Oncologist 22:1222–1231. https://doi.org/10.1634/theoncologist.2016-0414CrossRefPubMedPubMedCentral

26.

Sung H, Ferlay J, Siegel RL, Global Cancer Statistics et al (2020) GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660CrossRef

27.

Fuentes HE, Tafur AJ, Caprini JA (2016) Cancer-associated thrombosis. Dis Mon 62:121–158. https://doi.org/10.1016/j.disamonth.2016.03.003CrossRefPubMed

28.

Kourelis TV, Wysokinska EM, Wang Y et al (2014) Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. Lung Cancer 86:358–362. https://doi.org/10.1016/j.lungcan.2014.10.003CrossRefPubMed

29.

Jin YF, Ye YQ, Jin YJ (2022) Risk factors and impact on outcomes of Lung Cancer Patients concurrent with deep vein thrombosis. Cancer Control 29:10732748221145074. https://doi.org/10.1177/10732748221145074CrossRefPubMedPubMedCentral

30.

Howlett J, Benzenine E, Cottenet J et al (2020) Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study. BMC Cancer 20:461. https://doi.org/10.1186/s12885-020-06930-1CrossRefPubMedPubMedCentral

31.

Sun L, Aggarwal C (2020) Immunotherapy for lung Cancer-improving outcomes in patients with locally Advanced Non-Small Cell Lung Cancer with Immunotherapy. Cancer J 26:548–554. https://doi.org/10.1097/PPO.0000000000000485CrossRefPubMed

32.

Luciani A, Ghidini A, Borgonovo K et al (2022) Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: a systematic review. Tumori 3008916221122601. https://doi.org/10.1177/03008916221122601

33.

Reck M, Garassino MC, Imbimbo M (2018) Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer 120:62–69. https://doi.org/10.1016/j.lungcan.2018.03.025CrossRefPubMed

34.

Guo Q, Liu L, Chen Z (2022) Current treatments for non-small cell lung cancer. Front Oncol 12:945102. https://doi.org/10.3389/fonc.2022.945102CrossRefPubMedPubMedCentral

35.

Mansfield AS, Tafur AJ, Wang CE et al (2016) Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. J Thromb Haemost 14:1773–1778. https://doi.org/10.1111/jth.13378CrossRefPubMedPubMedCentral

36.

Nishimura A, Ikeda Y (2021) Yakugaku Zasshi 141:611–622. https://doi.org/10.1248/yakushi.20-00228CrossRefPubMed

37.

Wang Y, Attar BM, Fuentes HE et al (2018) Performance of Khorana risk score for prediction of venous thromboembolism in patients with hepatocellular carcinoma. Clin Appl Thromb Hemost 24:471–476. https://doi.org/10.1177/1076029617699088CrossRefPubMed

38.

VF NE F, S M, et al (2017) The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thromb Res 150:30–32. https://doi.org/10.1016/j.thromres.2016.12.013CrossRef

39.

Alma S, Eloi D, Léa V (2022) Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors. J Thromb Thrombolysis 54:287–294. https://doi.org/10.1007/s11239-022-02649-xCrossRefPubMed

40.

Thawani R, Kartika T, Elstrott B (2022) Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies. Thromb Res 217:12–14. https://doi.org/10.1016/j.thromres.2022.06.012CrossRefPubMedPubMedCentral

41.

Malka D, Girard N, Smadja DM (2022) Prévention et prise en charge des thromboses associées au cancer: questions pratiques à propos de l’anticoagulation [Prophylaxis and management of cancer-associated thrombosis: Practical issues about anticoagulant use. Bull Cancer 0007-4551 22 00424–6. https://doi.org/10.1016/j.bulcan.2022.10.008

Title: COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study
Authors: Hikmat Abdel-Razeq
Baha’ Sharaf
Mohammed J. Al-Jaghbeer
Hala Abu-Fares
Rayan Bater
Moataz Abu Shaer
Hala Abu-Jaish
Dima Abu Laban
Osama Salamah
Faris Tamimi
Khalid Ashouri
Tareq Salameh
Raed Zughul
Yazan Alhalaseh
Publication date: 11-07-2023
Publisher: Springer US
Keywords: NSCLC
NSCLC
Lung Cancer
Lung Cancer
Lung Cancer
Phlebothrombosis
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2023
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-023-02860-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies

Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population

Direct oral anticoagulants vs vitamin K antagonist on dementia risk in atrial fibrillation: systematic review with meta-analysis

Troponin dependent 30-day mortality in patients with acute pulmonary embolism

A nomogram for predicting the risk of venous thromboembolism in patients with solid cancers

Usefulness of the PRECISE-DAPT score at differentiating between ticagrelor and prasugrel for dual antiplatelet therapy initiation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials